Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

9.630 +0.020 (+0.21%)
Streaming Delayed Price Updated: 10:23 AM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,286
Open 9.700
Bid (Size) 9.620 (2)
Ask (Size) 9.640 (2)
Prev. Close 9.610
Today's Range 9.620 - 9.830
52wk Range 5.330 - 14.69
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Niagen Bioscience: 4 Analysts Share Their Views
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+24.4%
+24.4%
1 Month
-3.9%
-3.9%
3 Month
-31.9%
-31.9%
6 Month
+24.4%
+24.4%
1 Year
+24.4%
+24.4%

More News

Read More
Niagen NAGE Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Via Chartmill
Earnings Scheduled For August 6, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
What's Next: Niagen Bioscience's Earnings Preview
Via Benzinga
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
From Niagen Bioscience, Inc.
Via Business Wire
Examining the Future: Niagen Bioscience's Earnings Outlook
Via Benzinga
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate in the BIO 2025 International Convention
From Niagen Bioscience, Inc
Via Business Wire
What 4 Analyst Ratings Have To Say About Niagen Bioscience
Via Benzinga
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
From Niagen Bioscience, Inc
Via Business Wire
This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
From Niagen Bioscience, Inc
Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 9.630
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 09/15/25 10:23 AM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 656.73M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 657M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.